OxyContin monotherapy (Phase IIb)
Phase 2Protein / enzyme
OxyContin monotherapy (Phase IIb) is one of 43 small molecule programs targeting Cancer Pain. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
94 competitors in Cancer Pain
#DrugCompanyPhaseTrials
1MS Contin
Merck & Co.Phase 3
Medrol
PfizerPhase 3
Ketalar
AAultman Health Foundation
Phase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Advil
KKenvue Brands
Phase 3
Ultram
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Narcan
SScienture
Phase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Nacl
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 2[1]
- Company
- 33D Medicines